Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation.

Autor: Dzobo KE; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands.; Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, the Netherlands (K.E.D., M.V., J.K.)., Cupido AJ; Vascular Medicine (A.J.C., L.C.A.S., E.S.G.S.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Mol BM; Department of Vascular Surgery, University Medical Centre Utrecht, the Netherlands (B.M.M., D.P.V.d.K.)., Stiekema LCA; Vascular Medicine (A.J.C., L.C.A.S., E.S.G.S.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Versloot M; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands.; Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, the Netherlands (K.E.D., M.V., J.K.)., Winkelmeijer M; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Peter J; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Pennekamp AM; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Havik SR; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Vaz FM; Core Facility Metabolomics (F.M.V., M.v.W.), Amsterdam UMC, University of Amsterdam, the Netherlands., van Weeghel M; Core Facility Metabolomics (F.M.V., M.v.W.), Amsterdam UMC, University of Amsterdam, the Netherlands., Prange KHM; Department of Medical Biochemistry, Amsterdam Infection and Immunity (K.H.M.P., M.P.J.d.W.), Amsterdam UMC, University of Amsterdam, the Netherlands., Levels JHM; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., de Winther MPJ; Department of Medical Biochemistry, Amsterdam Infection and Immunity (K.H.M.P., M.P.J.d.W.), Amsterdam UMC, University of Amsterdam, the Netherlands., Tsimikas S; Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla (S.T.)., Groen AK; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., Stroes ESG; Vascular Medicine (A.J.C., L.C.A.S., E.S.G.S.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands., de Kleijn DPV; Department of Vascular Surgery, University Medical Centre Utrecht, the Netherlands (B.M.M., D.P.V.d.K.)., Kroon J; Departments of Experimental Vascular Medicine (K.E.D., M.V., M.W., J.P., A.-M.P., S.R.H., J.H.M.L., A.K.G., J.K.), Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands.; Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, the Netherlands (K.E.D., M.V., J.K.).; Laboratory of Angiogenesis and Vascular Metabolism, Flanders Institute for Biotechnology (VIB)-KU Leuven Center for Cancer Biology, VIB, Belgium (J.K.).; Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven and Leuven Cancer Institute, Belgium (J.K.).

Publikováno v: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2024 Mar; Vol. 44 (3), pp. 720-740. Date of Electronic Publication: 2024 Jan 25.

Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea.

Autor: Kaiser Y; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Dzobo KE; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Ravesloot MJL; Department of Otorhinolaryngology, OLVG, Amsterdam, the Netherlands; Department of Sleep Medicine, OLVG, Amsterdam, the Netherlands., Nurmohamed NS; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands., Collard D; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Hoogeveen RM; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Verberne HJ; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Dijkstra N; Department of Pulmonary Medicine, OLVG, Amsterdam, the Netherlands., de Vries N; Department of Otorhinolaryngology, OLVG, Amsterdam, the Netherlands; Department of Sleep Medicine, OLVG, Amsterdam, the Netherlands; Department of Oral Kinesiology, ACTA, Amsterdam, the Netherlands; Department of Otorhinolaryngology, University of Antwerp, Belgium., Bresser P; Department of Pulmonary Medicine, OLVG, Amsterdam, the Netherlands., Kroon J; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Stroes ESG; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Reesink HJ; Department of Sleep Medicine, OLVG, Amsterdam, the Netherlands; Department of Pulmonary Medicine, OLVG, Amsterdam, the Netherlands. Electronic address: h.j.reesink@olvg.nl.

Publikováno v: Atherosclerosis [Atherosclerosis] 2022 Mar; Vol. 344, pp. 7-12. Date of Electronic Publication: 2022 Jan 21.

Surmounting the endothelial barrier for delivery of drugs and imaging tracers.

Autor: Schnitzler JG; Amsterdam UMC, University of Amsterdam, Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, Netherlands., Dzobo KE; Amsterdam UMC, University of Amsterdam, Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, Netherlands., Nurmohamed NS; Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Cardiology, Amsterdam Cardiovascular Sciences, De Boelelaan, 1117, Amsterdam, the Netherlands., Stroes ESG; Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, Netherlands., Kroon J; Amsterdam UMC, University of Amsterdam, Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, Netherlands. Electronic address: j.kroon@amsterdamumc.nl.

Publikováno v: Atherosclerosis [Atherosclerosis] 2020 Dec; Vol. 315, pp. 93-101. Date of Electronic Publication: 2020 May 11.

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.

Autor: Wasiak S; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Dzobo KE; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Rakai BD; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Kaiser Y; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Versloot M; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Bahjat M; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Stotz SC; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Fu L; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Sweeney M; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Johansson JO; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Wong NCW; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Stroes ESG; Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Kroon J; Department of Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands., Kulikowski E; Resverlogix Corp, 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada. Ewelina@resverlogix.com.

Publikováno v: Clinical epigenetics [Clin Epigenetics] 2020 Nov 11; Vol. 12 (1), pp. 166. Date of Electronic Publication: 2020 Nov 11.

Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).

Autor: Stiekema LCA; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Prange KHM; Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Hoogeveen RM; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Verweij SL; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Kroon J; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Schnitzler JG; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Dzobo KE; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Cupido AJ; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., Tsimikas S; Ionis Pharmaceuticals, 2855 Gazelle Ct, Carlsbad, CA 92008, USA.; Sulpizio Cardiovascular Center, Vascular Medicine Program, University of California San Diego, 9434 Medical Center Dr, La Jolla, CA 92037, USA., Stroes ESG; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands., de Winther MPJ; Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Institute for Cardiovascular Prevention, IPEK, LMU, Pettenkoferstrasse 9, Munich 80336, Germany., Bahjat M; Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Publikováno v: European heart journal [Eur Heart J] 2020 Jun 21; Vol. 41 (24), pp. 2262-2271.